GRAYSON GRANT: Open Payments
NPI 1164098216 · JONESBORO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,074 in 124 payments from 21 companies in 2025. Trend: 2023 $2,519 · 2024 $2,016 · 2025 $2,074
Food & beverage: $2,074
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $423 |
| Janssen Biotech, Inc. | 16 | $320 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 18 | $303 |
| Madrigal Pharmaceuticals | 11 | $178 |
| Ardelyx, Inc. | 6 | $107 |
| Janssen Scientific Affairs, LLC | 1 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $90 |
| Lilly USA, LLC | 4 | $70 |
| Aimmune Therapeutics, Inc. | 4 | $68 |
| Regeneron Healthcare Solutions, Inc. | 2 | $64 |
Products named: TREMFYA, XIFAXAN, REZDIFFRA, LINZESS, RINVOQ, DUPIXENT, IBSRELA, RELISTOR.
Industry payments across AR — which companies pay providers there.
